In Vitro Influence of Specific Bacteroidales Strains on Gut and Liver Health Related to Metabolic Dysfunction-Associated Fatty Liver Disease

被引:1
|
作者
Garcia-Morena, Diego [1 ]
Fernandez-Cantos, Maria Victoria [1 ]
Escalera, Silvia Lopez [2 ,3 ]
Lok, Johnson [4 ]
Iannone, Valeria [4 ]
Cancellieri, Pierluca [1 ]
Maathuis, Willem [1 ]
Panagiotou, Gianni [5 ,6 ,7 ,8 ]
Aranzamendi, Carmen [9 ]
Aidy, Sahar El [9 ]
Kolehmainen, Marjukka [4 ]
El-Nezami, Hani [10 ]
Wellejus, Anja [2 ]
Kuipers, Oscar P. [1 ]
机构
[1] Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Mol Genet, Nijenborgh 7, NL-9747 AG Groningen, Netherlands
[2] Chr Hansen A S, Boge Alle 10-12, DK-2970 Horsholm, Denmark
[3] Friedrich Schiller Univ Jena, Fak Biowissensch, 18K,Bachstr, D-07743 Jena, Germany
[4] Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Sch Med, Kuopio 70200, Finland
[5] Leibniz Inst Nat Prod Res & Infect Biol Leibniz HK, Dept Microbiome Dynam, D-07745 Jena, Germany
[6] Univ Hong Kong, Dept Med, Hong Kong, Peoples R China
[7] Univ Hong Kong, State Key Lab Pharmaceut Biotechnol, Hong Kong, Peoples R China
[8] Friedrich Schiller Univ, Fac Biol Sci, D-07743 Jena, Germany
[9] Univ Groningen, Host Microbe Metab Interact, Groningen Biomol Sci & Biotechnol Inst GBB, Nijenborgh 7, NL-9747 AG Groningen, Netherlands
[10] Univ Hong Kong, Sch Biol Sci, Mol & Cell Biol Div, Pok Fu Lam, Hong Kong, Peoples R China
关键词
MAFLD; Microbiota; Bacteroidales; Antimicrobials; Fatty liver; Probiotics; MICROBIOTA; ANTIBIOTICS; EPIDEMIOLOGY; PREVALENCE; SILIBININ; SPECTRUM; OBESE; MICE;
D O I
10.1007/s12602-024-10219-1
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a major health risk and a serious worldwide issue. MAFLD typically arises from aberrant lipid metabolism, insulin resistance, oxidative stress, and inflammation. However, subjacent causes are multifactorial. The gut has been proposed as a major factor in health and disease, and over the last decade, bacterial strains with potentially beneficial effects on the host have been identified. In vitro cell models have been commonly used as an early step before in vivo drug assessment and can confer complementary advantages in gut and liver health research. In this study, several selected strains of the order Bacteroidales were used in a three-cell line in vitro analysis (HT-29, Caco-2, and HepG2 cell lines) to investigate their potential as new-generation probiotics and microbiota therapeutics. Antimicrobial activity, a potentially useful trait, was studied, and the results showed that Bacteroidales can be a source of either wide- or narrow-spectrum antimicrobials targeting other closely related strains. Moreover, Bacteroides sp. 4_1_36 induced a significant decrease in gut permeability, as evidenced by the high TEER values in the Caco-2 monolayer assay, as well as a reduction in free fatty acid accumulation and improved fatty acid clearance in a steatosis HepG2 model. These results suggest that Bacteroidales may spearhead the next generation of probiotics to prevent or diminish MAFLD.
引用
收藏
页码:1498 / 1512
页数:15
相关论文
共 50 条
  • [1] The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease
    Martin-Mateos, Rosa
    Albillos, Agustin
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [2] Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease
    Fouad, Yasser
    Alboraie, Mohamed
    Shiha, Gamal
    HEPATOLOGY INTERNATIONAL, 2024, 18 (SUPPL 2) : 827 - 833
  • [3] Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?
    Lanthier, Nicolas
    Delzenne, Nathalie
    CELLS, 2022, 11 (17)
  • [4] Metabolic dysfunction-associated fatty liver disease: a year in review
    Alharthi, Jawaher
    Gastaldelli, Amalia
    Cua, Ian Homer
    Ghazinian, Hasmik
    Eslam, Mohammed
    CURRENT OPINION IN GASTROENTEROLOGY, 2022, 38 (03) : 251 - 260
  • [5] The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease
    Goya, Takeshi
    Imoto, Koji
    Tashiro, Shigeki
    Aoyagi, Tomomi
    Takahashi, Motoi
    Kurokawa, Miho
    Suzuki, Hideo
    Tanaka, Masatake
    Kato, Masaki
    Kohjima, Motoyuki
    Ogawa, Yoshihiro
    GASTROENTEROLOGY INSIGHTS, 2022, 13 (01) : 20 - 26
  • [6] Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight
    Lopes Vasques-Monteiro, Isabela Macedo
    Souza-Mello, Vanessa
    WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (16) : 1738 - 1750
  • [7] Diabetes and metabolic dysfunction-associated fatty liver disease
    Davis, Timothy M. E.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 123
  • [8] Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
    Barchetta, Ilaria
    Cimini, Flavia Agata
    Cavallo, Maria Gisella
    NUTRIENTS, 2020, 12 (11) : 1 - 14
  • [9] Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease
    Sohn, Won
    Kwon, Heon-Ju
    Chang, Yoosoo
    Ryu, Seungho
    Cho, Yong Kyun
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (05) : E1135 - E1148
  • [10] Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers
    Liu, Zhenqiu
    Lin, Chunqing
    Suo, Chen
    Zhao, Renjia
    Jin, Li
    Zhang, Tiejun
    Chen, Xingdong
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2022, 127